Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEM-PRO: Neoadjuvant Pembrolizumab Before Radical Prostatectomy in High-risk Prostate Cancer
NCT04565496Phase 2Withdrawn
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Apr 2023
- Primary completion
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in prostate cancer (PCa), sponsored by IRCCS Ospedale San Raffaele. Planned start Apr 2023; status: withdrawn.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04565496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04565496.